Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (476)

« Back to Publications

Human haematopoietic stem cells remember inflammatory stress.

Zeng AGX. et al, (2026), Nature

Initial leukemic epigenomic state determines hypomethylating agent response.

Gopal A. et al, (2026), Nat Commun

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.

Lau I-J. et al, (2026), Blood

Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).

Papayannidis C. et al, (2026), Oncol Ther

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Turkalj S. et al, (2026), Blood, 147, 613 - 632

Dependent lineage regulatory programs in TP53-mutated acute myeloid leukemia revealed through deep single-cell multi-omic profiling of patient samples

Radtke FA. et al, (2026), CANCER RESEARCH, 86

High-resolution multi-omic dissection of bone marrow in TP53-mutant acute myeloid leukemia

Garcia GL. et al, (2026), CANCER RESEARCH, 86

Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Dohner H. et al, (2026), TRANSPLANTATION AND CELLULAR THERAPY, 32

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Nier S. et al, (2025), Future Oncol, 21, 3713 - 3719

ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

Vyas P. et al, (2025), Future Oncol, 21, 3721 - 3729

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Fetal Liver-Restricted Leukemic Proliferation Via GATA1s-CSF2RB-MPL Axis In Down Syndrome

Vyas P. et al, (2025)

Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome.

Elliott N. et al, (2025), Blood, 146, 1561 - 1574

Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome.

Li Y. et al, (2025), Blood Adv, 9, 4235 - 4243

Load More

1
2
3
4
5
6
7
...
»